Profil
Bruce Seligmann is associated with BioSypder Technologies, Inc. as the Chief Scientific Officer since 2012.
He is the founder of BioSypder Technologies, Inc. which was founded in 2012.
Aktive Positionen von Bruce Seligmann
| Unternehmen | Position | Beginn |
|---|---|---|
BioSypder Technologies, Inc.
 BioSypder Technologies, Inc. Medical SpecialtiesHealth Technology BioSpyder Technologies, Inc. is a biotechnology company based in Carlsbad, CA. BioSpyder Technologies has developed a novel product for targeted sequencing called Tempo-Seq, which is a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. Tempo-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. The assay content is flexible and customizable, delivering unprecedented accuracy and sensitivity with simplified data analysis that eliminates the need for bioinformatics. Tempo-Seq assays deliver an easy-to-use solution for customers doing expression profiling for any species. The private company was founded in 2011 by Joel McComb, Bruce Seligmann, and Joanne Yeakley, with Joel McComb serving as the CEO since then. | Gründer | 01.12.2012 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
BioSypder Technologies, Inc.
BioSypder Technologies, Inc. Medical SpecialtiesHealth Technology BioSpyder Technologies, Inc. is a biotechnology company based in Carlsbad, CA. BioSpyder Technologies has developed a novel product for targeted sequencing called Tempo-Seq, which is a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. Tempo-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. The assay content is flexible and customizable, delivering unprecedented accuracy and sensitivity with simplified data analysis that eliminates the need for bioinformatics. Tempo-Seq assays deliver an easy-to-use solution for customers doing expression profiling for any species. The private company was founded in 2011 by Joel McComb, Bruce Seligmann, and Joanne Yeakley, with Joel McComb serving as the CEO since then. | Health Technology |
